Protective effect of n-butanol extract from Alpinia oxyphylla on learning and memory impairments

Physiology and Behavior

Volumn 139, Issue , 2015, Pages 13-20

  Shi, Shao huai ^a   Zhao, Xu ^a   Liu, Ai jing ^a   Liu, Bing ^a   Li, Huan ^a   Wu, Bo ^a   Bi, Kai shun ^a   Jia, Ying ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Alpinia oxyphylla Miq.; Alzheimer's disease; A 1 42; Blood brain barrier

Indexed keywords

ALPINIA OXYPHYLLA EXTRACT; AMYLOID BETA PROTEIN[1-42]; BETA SECRETASE; BUTANOL; DONEPEZIL; GLUTATHIONE PEROXIDASE; MALONALDEHYDE; NEUROPROTECTIVE AGENT; PLANT EXTRACT; UNCLASSIFIED DRUG; (Z)2-(5-(4-METHOXYBENZYLIDENE)-2,4-DIOXOTHIAZOLIDIN-3-YL)ACETIC ACID; 2,4 THIAZOLIDINEDIONE DERIVATIVE; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); FRUIT EXTRACT, ALPINIA OXYPHYLLA; GLUTATHIONE; INDAN DERIVATIVE; NOOTROPIC AGENT; PEPTIDE FRAGMENT; PIPERIDINE DERIVATIVE; SECRETASE;

ACTIVE AVOIDANCE TEST; ALPINIA; ALPINIA OXYPHYLLA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; BRAIN CORTEX; BRAIN NERVE CELL; BRAIN PROTECTION; CONTROLLED STUDY; EXPERIMENTAL MODEL; FRONTAL CORTEX; FRUIT; HIPPOCAMPUS; LEARNING DISORDER; LIPID PEROXIDATION; MALE; MEMORY DISORDER; MORRIS WATER MAZE TEST; MOUSE; NERVE CELL NECROSIS; NONHUMAN; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; Y-MAZE TEST; ANIMAL; AVOIDANCE BEHAVIOR; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; INSTITUTE FOR CANCER RESEARCH MOUSE; LEARNING DISORDERS; MAZE TEST; MEMORY DISORDERS; METABOLISM; PHYTOTHERAPY;

1-BUTANOL; AMYLOID BETA-PEPTIDES; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; AVOIDANCE LEARNING; CEREBRAL CORTEX; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUTATHIONE; INDANS; LEARNING DISORDERS; MALE; MAZE LEARNING; MEMORY DISORDERS; MICE; MICE, INBRED ICR; NEUROPROTECTIVE AGENTS; NOOTROPIC AGENTS; PEPTIDE FRAGMENTS; PHYTOTHERAPY; PIPERIDINES; PLANT EXTRACTS; THIAZOLIDINEDIONES;

EID: 84911090880     PISSN: 00319384     EISSN: 1873507X     Source Type: Journal    
DOI: 10.1016/j.physbeh.2014.11.016     Document Type: Article

References (36)

1. Kawakami K., Kadota J., Iida K., Shirai R., Abe K., Kohno S. Reduced immune function and malnutrition in the elderly. Tohoku J Exp Med 1999, 187:157-171.
2. Hendrie H.C. Epidemiology of Alzheimer's disease. Geriatrics 1997, 52:S4-S8.
3. Alzheimer's Association Alzheimer's disease facts and figures. Alzheimers Dement 2010, 6:158-194. [6].
4. Butterfield D.A., Drake J., Pocernich C., Castegna A. Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid β-peptide. Trends Mol Med 2001, 7:548-554.
5. Masters C.L., Beyreuther K. Alzheimer's centennial legacy: prospects for rational therapeutic intervention targeting the β-amyloid pathway. Brain 2006, 129:2823-2839.
6. Choi S.H., Bosetti F. Cyclooxygenase-1 null mice show reduced neuroinflammation in response to beta-amyloid. Aging (Albany NY) 2009, 1:234-244.
7. Palop J.J., Mucke L. Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Nat Neurosci 2010, 13:812-818.
8. Schubert D., Behl C., Lesley R. Amyloid peptides are toxic via a common oxidative mechanism. Proc Natl Acad Sci U S A 1955, 92:1989-1993.
9. Yankner B.A. Mechanisms of neuronal degeneration in Alzheimer's disease. Neuron 1996, 16:921-932.
10. Inglis F. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia. Int J Clin Pract Suppl 2002, 45-63.
11. Doody R.S. Clinical profile of donepezil in the treatment of Alzheimer's disease. Gerontology 1999, 45:23-32.
12. Vanwyk B.E., Wink M. Medicinal plant of the world 2009, Briz Publication, South Africa. 1st ed.
13. Liu M.S. Introduction of Li nationality medicine 2008, 123-126. People's Medical Publishing House.
14. Wong K.K., Wan C.C., Shaw P.C. Ethanol extract of Alpinia oxyphylla fructus shows inhibition of tau protein phosphorylation in cell culture. Neurobiol Aging 2004, 25:595-597.
15. Yu X.Y., An L.J., Wang Y.Q., Zhao H., Gao C.Z. Neuroprotective effect of Alpinia oxyphylla Miq. fruits against glutamate-induced apoptosis in cortical neurons. Toxicol Lett 2003, 144:205-212.
16. Jia Y., He L.D., Fan Y., Sun X.H., You S.M., Yang X.C., et al. Progress of the chemical composition and pharmacological effects of the Alpinia oxyphylla Miq. J Jilin Med Coll 2012, 33:320-323. [33].
17. Muraoka O., Fujimoto M., Tanabe G., Kubo M., Minematsu T., Matsuda H., et al. Absolute stereostructures of novel norcadinane- and trinoreudesmane-type sesquiterpenes with nitric oxide production inhibitory activity from Alpinia oxyphylla. Bioorg Med Chem Lett 2001, 11:2217-2220.
18. Morikawa T., Matsuda H., Toguchida I., Ueda K., Yoshikawa M. Absolute stereo structures of three new sesquiterpenes from the fruit of Alpinia oxyphylla with inhibitory effects on nitric oxide production and degranulation in RBL-2H3 cell. J Nat Prod 2002, 645:1468-1474.
19. Luo X.Z., Yu J.G., Li K.M., Tan P., Feng J.D. Studies on the chemical constituents of the fruits from Alpinia oxyphylla. Acta Pharmacol Sin 2000, 35:204-207.
20. Zhang Q.F., Luo S.D., Wang H.Y., Fan D.Y. Studies on the chemical constituents of Yizhiren (Alpinia oxyphylla). Chin Tradit Herb Drugs 1997, 28:131-133.
21. Xu J.J., Tan N.H., Zeng G.Z., Han H.J., Huang H.Q., Ji C.J., et al. Studies on chemical constituents of Alpinia oxyphylla. Chin J Chin Mater Med 2009, 34:990-993.
22. Tsuda T., Horio F., Osawa T. Absorption and metabolism of cyaniding 3-O-β-D-glucoside in rats. FEBS Lett 1999, 449:179-182.
23. Yen G.C., Hsieh C.L. Inhibitory effects of Du-zhong (Eucommiaulmoides Oliv.) against low-density lipoprotein oxidative modification. Food Chem 2002, 77:449-456.
24. Pardridge W.M. Brain drug targeting; the future of brain drug development 2001, 1-370. Cambridge University Press, Cambridge. U.K.
25. Choi S.J., Heo M.J., Hong H.J., Cho H.Y., Kim Y.J., Kim H.K., et al. Ameliorating effect of Gardenia jasminoides extract on amyloid beta peptide-induced neuronal cell deficit. Mol Cells 2007, 24:113-118.
26. Paxinos G., Franklin K.B. The mouse brain in stereotaxic coordinates 2001, Academic Press, San Diego. 2nd ed.
27. Sarter M., Bodewitz G., Stephens D.N. Attenuation of scopolamine-induced impairment of spontaneous alternation behavior by antagonist but not inverse agonist and beta-carboline. Psychopharmacology (Berl) 1988, 94:491-495.
28. Laura A.L., Jesus L.F., Fernando P.C. Effects of chronic intracerebroventricular 3, 4-methylenedioxy-N-methamphetamine (MDMA) or fluoxetine on the active avoidance test in rats with or without exposure to mild chronic stress. Behav Brain Res 2009, 205:259-264.
29. Lu J., Zheng Y.L., Wu D.M. Ursolic acid ameliorates cognition deficits and attenuates oxidative damage in the brain of senescent mice induced by D-galactose. Biochem Pharmacol 2007, 74:1078-1090.
30. Xu J.J., Ji C.J., Zhang Y.M., Su J., Li Y., Tan N.H. Inhibitory activity of eudesmane sesquiterpenes from Alpinia oxyphylla on production of nitric oxide. Bioorg Med Chem Lett 2012, 22:1660-1663.
31. Hyman B.T., Hoesen G.W.V., Damasio A.R., Barnes C.L. Alzheimer's disease: cell-specific pathology isolates the hippocampal formation. Science 1984, 225:1168-1170.
32. Chinese Pharmacopoeia Commission Pharmacopoeia of the People's Republic of China 2010, 273-274. China Medical Science and Technology Press, Beijing.
33. Vari R., Archivio M.D., Filesi C., Carotenuto S., Scazzocchio B., Santangelo C., et al. Protocatechuic acid induces antioxidant/detoxifying enzyme expression through JNK-mediated Nrf2 activation in murine macrophages. J Nutr Biochem 2011, 22:409-417.
34. Rapta P., Misik V., Stasko A., Vrabel I. Redox intermediates of flavonoids and caffeic acid esters from propolis: an epr spectroscopy and cyclic coltammetry study. Free Radic Biol Med 1995, 18:901-908.
35. Banks W.A. Drug delivery to the brain in Alzheimer's disease: consideration of the blood-brain-barrier. Adv Drug Deliv Rev 2012, 64:629-639.
36. Rishton G.M., LaBonte K., Williams A.J., Kassam K., Kolovanov E. Computational approaches to the prediction of blood-brain barrier permeability: a comparative analysis of central nervous system drugs versus secretase inhibitors for Alzheimer's disease. Curr Opin Drug Discov 2006, 9:303-313.